ArticleMolecular therapy. Methods & clinical development2021
Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.
Article in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- Intravitreal delivery of NGF-chitosan hydrogel confers retinal ganglion cell protection and visual function recovery in experimental glaucoma.Bioactive materials · 2026Article
- Article
- Current Advances and Applications of Retinal Organoids.Neuroscience bulletin · 2026Review
- The internal limiting basement membrane inhibits functional engraftment of transplanted human retinal ganglion cells in vivo.Science translational medicine · 2026Article
- Photodisruption of the Inner Limiting Membrane Promotes Retinal Engraftment of Stem-Cell Derived Retinal Ganglion Cells.Investigative ophthalmology & visual science · 2026Article
- Enzymatic Disruption of the Internal Limiting Membrane Enhances Transplanted Retinal Ganglion Cell Survival.Investigative ophthalmology & visual science · 2026Article
- Human pluripotent stem cell-derived retinal ganglion cells: advances in differentiation and translational applications.Molecular medicine (Cambridge, Mass.) · 2025Review
- Optimizing tissue clearing methods for improved imaging of whole-mount retinas and optic nerves.Journal of neuroscience methods · 2025Article
- Sustained Neurotrophic Factor Co-Treatment Enhances Donor and Host Retinal Ganglion Cell Survival in Mice.Translational vision science & technology · 2025Article
- Retinal ganglion cell migration and viability requires the kinase LKB1.The Journal of cell biology · 2025Article
- Single-cell transcriptome of retinal myeloid cells in response to transplantation of human neurons reveals reversibility of microglial activation.bioRxiv : the preprint server for biology · 2025Article
- The neuroimmune interface in retinal regeneration.Progress in retinal and eye research · 2025Review
- Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The application of retinal organoids in ophthalmic regenerative medicine: A mini-review.Regenerative therapy · 2024Review
- The hope, hype and obstacles surrounding cell therapy.Journal of cellular and molecular medicine · 2024Review
- Cell replacement with stem cell-derived retinal ganglion cells from different protocols.Neural regeneration research · 2024Review
- Cell adhesion and actin dynamics factors promote axonal extension and synapse formation in transplanted Drosophila photoreceptor cells.Development, growth & differentiation · 2024Article
- Mechanical Disruption of the Inner Limiting Membrane In Vivo Enhances Targeting to the Inner Retina.Investigative ophthalmology & visual science · 2023Article
- The Retinal Ganglion Cell Repopulation, Stem Cell Transplantation, and Optic Nerve Regeneration Consortium.Ophthalmology science · 2023Article
- Controlling donor and newborn neuron migration and maturation in the eye through microenvironment engineering.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Optic neuropathies, including glaucoma, are a group of neurodegenerative diseases, characterized by the progressive loss of retinal ganglion cells (RGCs), leading to irreversible vision loss. While previous studies demonstrated the potential to replace RGCs with primary neurons from developing mouse retinas, their use is limited clinically. We demonstrate successful transplantation of mouse induced pluripotent stem cell (miPSC)/mouse embryonic stem cell (mESC)-derived RGCs into healthy and glaucomatous mouse retinas, at a success rate exceeding 65% and a donor cell survival window of up to 12 months. Transplanted Thy1-GFP+ RGCs were able to polarize within the host retina and formed axonal processes that followed host axons along the retinal surface and entered the optic nerve head. RNA sequencing of donor RGCs re-isolated from host retinas at 24 h and 1 week post-transplantation showed upregulation of cellular pathways mediating axonal outgrowth, extension, and guidance. Additionally, we provide evidence of subtype-specific diversity within miPSC-derived RGCs prior to transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.